SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001737287-21-000051
Filing Date
2021-11-04
Accepted
2021-11-04 16:20:37
Documents
63
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q allo-20210930.htm   iXBRL 10-Q 1602197
2 EX-31.1 allo-20210930xex311.htm EX-31.1 9890
3 EX-31.2 allo-20210930xex312.htm EX-31.2 9860
4 EX-32.1 allo-20210930xex321.htm EX-32.1 7124
  Complete submission text file 0001737287-21-000051.txt   6729983

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT allo-20210930.xsd EX-101.SCH 42622
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT allo-20210930_cal.xml EX-101.CAL 53305
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT allo-20210930_def.xml EX-101.DEF 267386
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT allo-20210930_lab.xml EX-101.LAB 570209
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT allo-20210930_pre.xml EX-101.PRE 375437
10 EXTRACTED XBRL INSTANCE DOCUMENT allo-20210930_htm.xml XML 1066777
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

IRS No.: 823562771 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38693 | Film No.: 211380313
SIC: 2836 Biological Products, (No Diagnostic Substances)